Luca Giovanella1, Giorgio Treglia2, Ioannis Iakovou3, Jasna Mihailovic4, Frederik A Verburg5, Markus Luster5. 1. Clinic for Nuclear Medicine and Thyroid Competence Centre, Imaging Institute of Southern Switzerland, Via Ospedale 6, CH-6500, Bellinzona, Switzerland. Luca.Giovanella@eoc.ch. 2. Clinic for Nuclear Medicine and Thyroid Competence Centre, Imaging Institute of Southern Switzerland, Via Ospedale 6, CH-6500, Bellinzona, Switzerland. 3. Academic Department of Nuclear Medicine, Papageorgiu Hospital, Thessaloniki, Greece. 4. Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia. 5. Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
Abstract
BACKGROUND: Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure. METHODS: Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (18F-FDG), fluorine-18 dihydroxyphenylalanine (18F-FDOPA) and somatostatin analogues labelled with gallium-68 (68Ga-SSA) tracks different metabolic pathways or receptor expression/functioning, and proved to be useful in detecting MTC recurrences/metastasis. CONCLUSIONS: This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature's evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
BACKGROUND: Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure. METHODS: Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (18F-FDG), fluorine-18 dihydroxyphenylalanine (18F-FDOPA) and somatostatin analogues labelled with gallium-68 (68Ga-SSA) tracks different metabolic pathways or receptor expression/functioning, and proved to be useful in detecting MTC recurrences/metastasis. CONCLUSIONS: This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature's evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
Authors: Giorgio Treglia; Fabrizio Cocciolillo; Francesco Di Nardo; Andrea Poscia; Chiara de Waure; Alessandro Giordano; Vittoria Rufini Journal: Acad Radiol Date: 2012-07-20 Impact factor: 3.173
Authors: E Modigliani; R Cohen; J M Campos; B Conte-Devolx; B Maes; A Boneu; M Schlumberger; J C Bigorgne; P Dumontier; L Leclerc; B Corcuff; I Guilhem Journal: Clin Endocrinol (Oxf) Date: 1998-03 Impact factor: 3.478
Authors: Anja T Golubić; Eva Pasini Nemir; Marijan Žuvić; Andrea Mutvar; Sanja Kusačić Kuna; Marija Despot; Tatjana Samardžić; Dražen Huić Journal: Nucl Med Commun Date: 2017-07 Impact factor: 1.690
Authors: P Gómez-Camarero; A Ortiz-de Tena; I Borrego-Dorado; R J Vázquez-Albertino; E Navarro-González; J V Ruiz-Franco-Baux; J I Cuenca-Cuenca Journal: Rev Esp Med Nucl Imagen Mol Date: 2011-08-03 Impact factor: 1.359
Authors: Cristina Emiko Ueda; Paulo Schiavom Duarte; Luciana Audi de Castroneves; George Barbério Coura-Filho; Heitor Naoki Sado; Marcelo Tatit Sapienza; Ana Oliveira Hoff; Carlos Alberto Buchpiguel Journal: Nucl Med Mol Imaging Date: 2020-09-28
Authors: Christian Uprimny; Elisabeth von Guggenberg; Anna Svirydenka; Renata Mikołajczak; Alicja Hubalewska-Dydejczyk; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2020-08-03 Impact factor: 9.236